EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling
Authors:
- William C. ArnoldWAWilliam C. Arnold
- Durga Meenakshi PanneerdossDPDurga Meenakshi Panneerdoss
- Baskaran SubramaniBSBaskaran Subramani
- Megharani MahajanMMMegharani Mahajan
- Behnam EbrahimiBEBehnam Ebrahimi
- Paulina RamirezPRPaulina Ramirez
- Bindu SanthammaBSBindu Santhamma
- Suryavathi ViswanadhapalliSVSuryavathi Viswanadhapalli
- Edward R. KostEKEdward R. Kost
- Yidong ChenYCYidong Chen
- Zhao LaiZLZhao Lai
- Hareesh B. NairHNHareesh B. Nair
Open Access
- 30 September 2025
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1396
Abstract
Ovarian cancer (OCa) remains the most lethal gynecologic malignancy in the United States, with low-grade serous and mucinous subtypes frequently driven by KRAS mutations. These mutations activate downstream MAPK and PI3K/AKT signaling pathways, contributing to tumor progression and resistance to therapy. Although the MEK inhibitor trametinib is used to target these pathways, its efficacy is limited in KRAS-mutant OCa due to compensatory activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) axis. In this study, we evaluated the therapeutic potential of combining trametinib with EC359, a selective LIFR inhibitor, in Ras/Raf-driven OCa models. EC359 significantly reduced cell viability, clonogenic survival, and induced cell death via ferroptosis in vitro. Mechanistic studies revealed that EC359 suppressed trametinib-induced activation of LIFR downstream signaling. RNA-seq analysis showed that combination therapy downregulated mitochondrial translation and MYC target genes while upregulating apoptosis-related genes. In vivo, EC359 and trametinib co-treatment significantly reduced tumor growth in xenograft and PDX models without inducing toxicity. Our studies identify LIFR signaling as a critical vulnerability in Ras/Raf-mutant and low grade serous OCa. Further, it provides strong preclinical rationale for EC359 and trametinib combination therapy as a new therapeutic strategy for treating Ras/Raf-driven OCa and low-grade serous OCa.Keywords
Funding Information
- MCC Pilot grant (NIH R01 CA267893, NIH R01 CA266970-01A1, VA I01 BX006280-01, NCI F99 CA284284-01, NIH NCI R50 CA265339)
- AstraZeneca Young Investigator Award
- Cancer Center at UT Health San Antonio (NIH-NCI P30 CA054174)
- NIH Shared Instrumentation (1S10 OD030311-01)
- the CPRIT Core Facility Award (RP220662)
This publication has 28 references indexed in Scilit:
- The LIFR-targeting small molecules EC330/EC359 are potent ferroptosis inducersGenes & Diseases, 2023
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialThe Lancet, 2022
- LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancerCell Death Discovery, 2021
- The emerging role of leukemia inhibitory factor in cancer and therapyPharmacology & Therapeutics, 2021
- MEK inhibitor resistance mechanisms and recent developments in combination trialsCancer Treatment Reviews, 2021
- Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceCancer, 2019
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated CancersDrugs, 2018
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerNature Reviews Cancer, 2015
- Leukemia inhibitory factor (LIF)Cytokine & Growth Factor Reviews, 2015
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012